Table 1 Clinical and biochemical characteristics of patients with FCHL and control subjects
From: Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment
Cases (n = 59) | Controls (n = 48) | P | |
|---|---|---|---|
Age (years) | 50.2 ± 11.6 | 46.5 ± 17.2 | 0.210 |
Sex (% men) | 57.6 | 62.5 | 0.609 |
BMI (Kg/m2) | 27.9 ± 4.1 | 25.4 ± 4.1 | 0.005 |
Waist (cm) | 0.026 | ||
- Men | 97.7 ± 9 | 91.79 ± 12.1 | |
- Women | 92.7 ± 12.4 | 88.8 ± 11.8 | |
Glucose (mmol/L) | 5.3 ± 0.6 | 4.9 ± 0.73 | 0.020 |
HbA1c (%) | 5.6 ± 0.5 | 5.4 ± 0.6 | 0.135 |
Total cholesterol (mmol/L) | 6.7 ± 1.6 | 4.8 ± 0.8 | 0.000 |
Triglycerides (mmol/L) | 2.3 (1.1-15.8) | 0.7 (0.3-2.1) | 0.000 |
LDL-c (mmol/L) | 4.1 ± 1.3 | 2.8 ± 0.7 | 0.000 |
HDL-c (mmol/L) | 1.2 ± 0.4 | 1.6 ± 0.4 | 0.000 |
VLDL-c (mmol/L) | 1.0 (0.5-7.6) | 0.4 (0.1-1.2) | 0.000 |
NEFA (mmol/L) | 0.7 (0.2-4.3) | 0.4 (0.1-1.1) | 0.000 |
ApoB (g/L) | 1.3 ± 0.3 | 0.8 ± 0.2 | 0.000 |
CRP (mg/L) | 1.6 (0.2-21.5) | 1.0 (0.2-15.0) | 0.133 |
25(OH)D (nmol/L) | 58.9 ± 24.5 | 69.1 ± 30.0 | 0.057 |